$ELAN · Elanco Animal Health Inc
Elanco reported Q3 FY2026 (ended Sept 30, 2026) revenue of $1.265B, up 11% reported and 9% organic constant currency. Reported net income was $18M ($0.04 EPS) versus a $34M loss a year ago; adjusted net income was $136M ($0.27 EPS), up 42% on adjusted EPS. Adjusted EBITDA rose 23% to $243M with margin of 19.5%. The company raised FY2026 guidance: revenue to $5.155B-$5.18B, adjusted EBITDA to $1.05B-$1.065B, and adjusted EPS to $1.17-$1.20, and reached a 2.9x net leverage ratio.
- Revenue $1.265B, +11% reported, +9% organic constant currency.
- Adjusted EPS $0.27, up 42% from $0.19 a year ago.
- Adjusted EBITDA $243M, +23%, margin 19.5%.
- FY26 guidance raised: revenue $5.155B-$5.18B, adjusted EPS $1.17-$1.20.
- Net leverage ratio improved to 2.9x adjusted EBITDA.
Extended-hours last trade $25.40, +7.31% vs regular close of $23.67, indicating a positive after-hours reaction to the beat and raised guidance.
Elanco beat on revenue and EPS while raising full-year guidance and hitting its 2.9x leverage milestone, signaling accelerating innovation-driven growth.
Pet Health led with 14% growth on Zenrelia and Credelio Quattro share gains, while Farm Animal grew 6%.
Seresto revenue was negatively impacted by U.S. retailer inventory drawdown; Poultry revenue declined 7%.